Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

Launched by EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER - EORTC · Feb 17, 2022

Keywords

ClinConnect Summary

This clinical trial is an observational study that aims to understand how patients with certain types of primary brain tumors, like gliomas and other rare tumors, are treated and what outcomes they experience. The study is looking at a new way to classify these tumors called the 2021 WHO classification, which may help doctors group patients more accurately and develop better treatment recommendations. By collecting information from patients and their treatments, researchers hope to create guidelines that will improve care for individuals with these newly defined tumor types.

To take part in the study, participants should be adults aged 65 and older who have been newly diagnosed or have recurring primary brain tumors, especially those that are considered rare. They will need to provide a sample of their tumor tissue and give consent to participate. The trial is currently recruiting and will involve gathering data on patient experiences and treatment outcomes, which will help shape future treatment strategies for these complex conditions. Participants can expect to contribute to valuable research that may benefit others facing similar challenges in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Newly diagnosed or recurrent primary brain tumours, notably those considered rare brain tumours or rare subtypes of common brain tumours.
• • Archival tumour tissue from primary tumour available at the site. Representative tissue from first surgery is preferred, but tissue from surgery for recurrence is allowed.
• • Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.
• • Inclusion in interventional studies prior and after